Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vudalimab in Selected Advanced Solid Tumors
NCT03517488Phase 1Completed
- Sponsor
- Xencor
- Start
- Jul 2018
- Primary completion
- Jun 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vudalimab in melanoma, Triple-negative breast carcinoma (TNBC), hepatocellular carcinoma (HCC) and 25 more, sponsored by Xencor. Primary endpoint: Safety and Tolerability of XmAb20717 at 56 Days. Started Jul 2018; status: completed.
02
Drugs
vudalimab
03
Conditions
melanomaTriple-negative breast carcinoma (TNBC)hepatocellular carcinoma (HCC)urothelial carcinoma (UC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03517488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517488.